Apogee Therapeutics, Inc Common Stock

Yahoo Finance • 3 days ago

Apogee Therapeutics to Participate in Upcoming March Conferences

SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tu... Full story

Yahoo Finance • 4 days ago

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million

On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines(NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on quarterly average pricing, according to its... Full story

Yahoo Finance • 4 days ago

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics(NASDAQ:APGE), with an estimated transaction value of $61.64 million based on quarterly average pricing. What happened According to a Febru... Full story

Yahoo Finance • 5 days ago

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges

Perceptive Advisors disclosed a sale of 1,002,282 Arcellx(NASDAQ:ACLX) shares in a February 17, 2026, SEC filing, with the estimated transaction value at $79.96 million based on quarterly average pricing. What happened According to a SEC... Full story

Yahoo Finance • 11 days ago

Here is Why Apogee Therapeutics (APGE) Appears Attractive

Apogee Therapeutics (NASDAQ:APGE) is one of the 17 biotechnology stocks with more than 50% upside. On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics (NASDAQ:APGE), with a $95 price target. His foreca... Full story

Yahoo Finance • 13 days ago

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress

On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines(NASDAQ:PRAX), acquiring 185,000 shares in an estimated $54.53 million trade. What happened According to a SEC filing dated February 13,... Full story

Yahoo Finance • 13 days ago

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million

On February 13, 2026, Affinity Asset Advisors disclosed a purchase of 61,500 shares of Apogee Therapeutics(NASDAQ:APGE), an estimated $3.87 million trade based on quarterly average pricing. What happened According to an SEC filing dated... Full story

Yahoo Finance • 4 months ago

Apogee Therapeutics reports Q3 results

* Apogee Therapeutics press release [https://seekingalpha.com/pr/20300096-apogee-therapeutics-announces-positive-interim-phase-1-results-from-healthy-volunteer-trial] (APGE [https://seekingalpha.com/symbol/APGE]): Q3 Net loss was $65.0 m... Full story

Yahoo Finance • 4 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B... Full story

Yahoo Finance • 4 months ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing Results suppo... Full story

Yahoo Finance • 4 months ago

Apogee Therapeutics to Participate in Upcoming Conferences

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2nd Annual Healthcare I... Full story

Yahoo Finance • 5 months ago

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest in... Full story

Yahoo Finance • 5 months ago

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi. Continue Reading View Comments... Full story

Yahoo Finance • 5 months ago

Biggest stock movers Thursday: AZZ, RELL, and more

[Candlestick chart and data of financial market.] tadamichi Stock futures were largely unchanged in premarket trading on Thursday, following a strong tech rally that pushed the Nasdaq to a new record high in the previous session. Here ar... Full story

Yahoo Finance • 5 months ago

Apogee Therapeutics prices $300M public offering

* Apogee Therapeutics (NASDAQ:APGE [https://seekingalpha.com/symbol/APGE]) priced its public offering at $41 per share, raising ~$300M in gross proceeds. * The offering includes 6.95M common shares and 365,853 pre-funded warrants price... Full story

Yahoo Finance • 5 months ago

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest in... Full story

Yahoo Finance • 5 months ago

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest in... Full story

Yahoo Finance • 5 months ago

BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best up and coming stocks with huge upside potential. On August 28, BofA analyst Tim Anderson raised the firm’s price target on Apogee Therapeutics to $87 from $78, while keeping a Buy r... Full story

Yahoo Finance • 6 months ago

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest... Full story

Yahoo Finance • 6 months ago

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation... Full story